Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis
- PMID: 16265698
Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis
Abstract
Objective: To assess the contribution of 2 polymorphisms within the inducible nitric oxide (NOS2A) promoter region to susceptibility to giant cell arteritis (GCA).
Methods: One hundred three patients with biopsy-proven GCA and 198 ethnically matched controls from the Lugo region (Northwest Spain) were studied. Patients and controls were genotyped using polymerase chain reaction techniques for a multiallelic (CCTTT)n and for the TAAA repeat polymorphism in the promoter region of the NOS2A gene.
Results: No significant differences in allele or genotype frequencies for the (CCTTT)n repeat polymorphism in the NOS2A gene between patients with GCA and controls were observed. However, significant differences for the TAAA repeat polymorphism between patients and controls were found. The overall distribution of NOS2A TAAA genotypes in patients with biopsy-proven GCA was significantly different than controls (p = 0.026). Patients with GCA had an increased frequency of the NOS2A TAAA+ allele (16.5%) compared with controls (9.1%) (p = 0.007; OR 1.98; 95% CI 1.20-3.27). This was due to an increased frequency of both heterozygotes (27.2%) and homozygotes (2.9%) for NOS2A TAAA+ observed in patients compared to controls (15.2% and 1.5%, respectively) (p = 0.007; OR 2.15; 95% CI 1.23-3.78).
Conclusion: Our results suggest a potential implication for NOS2A TAAA gene polymorphism in GCA susceptibility.
Similar articles
-
Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis.J Rheumatol. 2008 May;35(5):850-4. J Rheumatol. 2008. PMID: 18381780
-
Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis.J Rheumatol. 2003 Sep;30(9):2019-22. J Rheumatol. 2003. PMID: 12966609
-
Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain.J Rheumatol. 2006 Feb;33(2):285-8. J Rheumatol. 2006. PMID: 16465659
-
Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.Semin Arthritis Rheum. 2003 Aug;33(1):38-48. doi: 10.1053/sarh.2002.50025. Semin Arthritis Rheum. 2003. PMID: 12920695 Review.
-
Cytokine gene considerations in giant cell arteritis: IL10 promoter polymorphisms and a review of the literature.Clin Rev Allergy Immunol. 2014 Aug;47(1):56-64. doi: 10.1007/s12016-013-8405-8. Clin Rev Allergy Immunol. 2014. PMID: 24395029 Review.
Cited by
-
Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility.Immunogenetics. 2007 Nov;59(11):833-7. doi: 10.1007/s00251-007-0255-1. Epub 2007 Oct 23. Immunogenetics. 2007. PMID: 17955236
-
Mechanism and biomarkers in aortitis--a review.J Mol Med (Berl). 2020 Jan;98(1):11-23. doi: 10.1007/s00109-019-01838-1. Epub 2019 Oct 30. J Mol Med (Berl). 2020. PMID: 31664480 Review.
-
Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.Arthritis Res Ther. 2010;12(2):R51. doi: 10.1186/ar2962. Epub 2010 Mar 23. Arthritis Res Ther. 2010. PMID: 20331879 Free PMC article.
-
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy.Sci Rep. 2017 Mar 9;7:43953. doi: 10.1038/srep43953. Sci Rep. 2017. PMID: 28277489 Free PMC article.
-
Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.Drugs Aging. 2006;23(8):627-49. doi: 10.2165/00002512-200623080-00002. Drugs Aging. 2006. PMID: 16964987 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical